Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands

A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor wherein said disorder is a psychiatric disorder or a neurodegenerative disorder in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I

• wherein
• Q is SO2, CO, CONR9 or CSNR10;
• n is an integer of 2 or 3;
• R1 and R2 are each independently H, halogen, CN, OCO2R12, CO2R13, CONR14R15, CNR16NR17R18, SOmR19, NR20R21, OR22, COR23 or a C1–C6alkyl, C2–C6alkenyl, C2–C6alkynyl, C3–C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R3 and R4 are each independently H or an optionally substituted C1–C6alkyl group;
• R5 and R6 are each independently H or a C1–C6alkyl, C2–C6alkenyl, C2–C6alkynyl, C3–C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted, or R5 and R6 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S;
• R7 is H, halogen, or a C1–C6alkyl, C1–C6alkoxy, aryl or heteroaryl group each optionally substituted;
• R8 is an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
• m is 0 or an integer of 1 or 2;
• R9 and R10 are each independently H or a C1–C6alkyl, aryl or heteroaryl group each optionally substituted;
• R12, R13, R19 and R23 are each independently H or a C1–C6alkyl, C2–C6alkenyl, C2–C6alkynyl, C3–C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R14, R15 and R22 are each independently H or an optionally substituted C1–C6alkyl group;
• and
• R16, R17, R18, R20 and R21 are each independently H or an optionally substituted C1–C4alkyl group;
• or R20 and R21 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
• or
• the stereoisomers thereof or the pharmaceutically acceptable salts thereof.